<DOC>
	<DOCNO>NCT01727271</DOCNO>
	<brief_summary>This study compare monotherapy tenofovir sequential therapy pegylated interferon alpha-2b ( pegIFN-2b ) follow tenofovir , combination therapy pegIFN-2b + tenofovir , participant hepatitis B e antigen ( HBeAg ) -positive chronic hepatitis B elevate alanine aminotransferase ( ALT ) . All enrol participant administer tenofovir alone 8 week randomly assign 1 3 treatment arm .</brief_summary>
	<brief_title>A Study Compare Efficacy Safety Tenofovir Used Alone Combination With Pegylated Interferon Alpha-2b Participants With Chronic Hepatitis B Elevated Alanine Aminotransferase ( MK-4031-384 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Chronic hepatitis B ( hepatitis B surface antigen [ HBsAg ] positive &gt; 6 month evidence chronic hepatitis B liver biopsy ) Elevated serum ALT level Liver biopsy noninvasive investigation within 12 month prior randomization Chronic Hepatitis B Treatment na√Øve history interferon 1 month , take least 6 month enrollment Compensated liver disease Known hypersensitivity tenofovir , interferon alpha2b , and/or component study product Coinfection hepatitis C virus ( HCV ) , hepatitis D virus ( HDV ) human immunodeficiency virus ( HIV ) Need prolonged frequent use systemic acyclovir famciclovir Previously receive lamivudine investigational antihepatitis B virus ( HBV ) nucleoside nucleotide analog resistant drug History variceal bleed GI bleed due portal hypertension , hepatic encephalopathy , spontaneous bacterial peritonitis , Grade III IV esophageal varix unless band clinical sign hepatic decompensation History hepatocellular carcinoma ( HCC ) finding suggestive possible HCC Need potentially hepatotoxic drug ( e.g . dapsone , erythromycin , fluconazole , ketoconazole , rifampin , antituberculosis regimen ) nephrotoxic drug ( e.g . frequent nonsteroidal antiinflammatories , aminoglycosides , amphotericin B , foscarnet ) One additional know primary secondary cause liver disease , hepatitis B History clinical pancreatitis Pregnant breastfeed Female participant childbearing potential male participant must willing use acceptable method birth control . Medical condition require frequent prolong use systemic corticosteroid Use warfarin anticoagulant 30 day prior screen expect needed study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>